Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Global Alliance to Develop Class-Leading Technology

Published: Wednesday, January 22, 2014
Last Updated: Wednesday, January 22, 2014
Bookmark and Share
BRET technologies for real-time monitoring of molecular interactions.

A team of world leaders in the growing scientific field of biomolecular interaction, relating to basic biomedical research and the discovery of new pharmaceuticals, has been the recipient of a new Australian Research Council Linkage Grant.

The project combines the knowledge and expertise of the laboratories of Associate Professor Kevin Pfleger of The University of Western Australia/Harry Perkins Institute of Medical Research and Professor Stephen Hill of The University of Nottingham (UK) who are both leaders in bioluminescence resonance energy transfer (BRET)/fluorescence technology development. They will be working with the bioluminescent industry leader Promega Corporation and the leading high-throughput instrumentation company BMG Labtech Pty Ltd (Australia).

The group will work to develop class-leading BRET technologies for real-time monitoring of molecular interactions.

Associate Professor Kevin Pfleger said the integrated international approach was critical for the development of the best technology, enabling academics, biotechnology and pharmaceutical companies to discover novel treatments with fewer side effects for a range of disorders, including cancer.

“Working together to develop the assay approach, reagents and instrumentation will enable class-leading high throughput and real-time resonance energy transfer assays to be established, specifically to monitor G protein-coupled receptor pharmacology in live cells,” he said.

“It’s expected that the proposed assay systems will be major advances for the biotechnology and pharmaceutical industries, significantly improving pharmaceutical development, both in terms of identifying novel compounds of interest and better understanding the biochemical basis of pharmacological activity,” he said.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

25 Years of Revolutionary Microplate Reader Technology at the LS2
BMG LABTECH exhibits at the biggest Swiss Life Sciences Meeting for the first time.
Tuesday, December 16, 2014
BMG LABTECH Announces First FP User Group Meeting
The meeting brings together a wide range of speakers with extensive experience of Fluorescence Polarization techniques.
Monday, April 26, 2010
BMG LABTECH Announces First FP User Group Meeting
Company announces their inaugural UK Fluorescence Polarisation user group meeting on the 23rd of April 2010.
Monday, April 19, 2010
BMG LABTECH, World Leader in Microplate Reader Technology, is proud to be a Bronze Sponsor of the SBS Conference 2010.
Visit us at booth 817 and join us at our workshops to see latest innovations in microplate reading technology including the ultimate HTS Microplate Reader, PHERAstar FS
Tuesday, March 30, 2010
BMG Labtech Joins ALSSA
The ALSSA - Analytical & Life Science Systems Association - Board of Directors recently approved applications for membership submitted by BMG LABTECH, Inc. Based in Cary, North Carolina.
Thursday, March 25, 2010
DLReady Certification for the Omega Series of Microplate Readers
DLReady certification, awarded by Promega Corp., validates an instrument that has passed the strict performance levels and standards required for the Dual-Luciferase Reporter (DLR) assay system.
Monday, December 03, 2007
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!